Gilead Sciences Inc. (GILD)

72.72
1.29 1.74
NASDAQ : Health Technology
Prev Close 74.01
Open 74.08
Day Low/High 72.26 / 74.30
52 Wk Low/High 63.76 / 89.54
Volume 5.39M
Avg Volume 7.73M
Exchange NASDAQ
Shares Outstanding 1.30B
Market Cap 96.09B
EPS 3.50
P/E Ratio 20.82
Div & Yield 2.28 (2.86%)

Latest News

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Why Uber's Self-Driving Car Fatality Won't End Autonomous Driving

Why Uber's Self-Driving Car Fatality Won't End Autonomous Driving

The fatality that came at the hands of a self-driving Uber vehicle was tragic. But keep in mind, self-driving cars will be safer than human drivers in the not-too-distant future.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

Gilead Sciences' Norbert Bischofberger, PhD, To Step Down; John McHutchison, MD, Appointed Chief Scientific Officer And Andrew Cheng, MD, PhD, Appointed Chief Medical Officer

Gilead Sciences' Norbert Bischofberger, PhD, To Step Down; John McHutchison, MD, Appointed Chief Scientific Officer And Andrew Cheng, MD, PhD, Appointed Chief Medical Officer

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at...

Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched To Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) From A Boosted Protease Inhibitor-Based Regimen Or Boosted Elvitegravir-Containing Regimen

Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched To Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) From A Boosted Protease Inhibitor-Based Regimen Or Boosted Elvitegravir-Containing Regimen

Gilead Sciences, Inc. (NASDAQ: GILD) today announced 48-week results from a Phase 3 study (Study 1961) of 470 virologically suppressed adult women with HIV infection, evaluating the efficacy and safety of switching from a...

Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched To Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) From Regimen Containing Abacavir, Dolutegravir And Lamivudine

Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched To Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) From Regimen Containing Abacavir, Dolutegravir And Lamivudine

Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week results from a Phase 3 study (Study 1844) evaluating the efficacy and safety of switching from a regimen containing abacavir, dolutegravir and lamivudine...

Gilead Announces Data From New Preclinical Study Evaluating A Combination Of An Investigational TLR7 Agonist And An Investigational HIV Envelope Targeting Antibody In SHIV-Infected, Virally Suppressed Monkeys

Gilead Announces Data From New Preclinical Study Evaluating A Combination Of An Investigational TLR7 Agonist And An Investigational HIV Envelope Targeting Antibody In SHIV-Infected, Virally Suppressed Monkeys

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating the combination of a proprietary...

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

20 Stock Picks to Weather Any Storm From Trade Wars to Fed Rate Hikes

Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?

Gilead Sciences Announces Senior Management Change

Gilead Sciences Announces Senior Management Change

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that James Meyers, Executive Vice President, Commercial Operations, will retire.

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

Kite, A Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

-- Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology --

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

A steeper fall might cause both buyers and sellers to re-think potential deals, but so far that doesn't seem to be the case yet.

Gilead Sciences To Present At The RBC Capital Markets 2018 Global Healthcare Conference On Wednesday, February 21

Gilead Sciences To Present At The RBC Capital Markets 2018 Global Healthcare Conference On Wednesday, February 21

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABC, ACXM, ADM, APC, IT, NOV, PXD, TPR, VSM Downgrades: AGX, CMCO, CMI, FARM, FFWM, GILD, GLAD, GRAM, HAE, KT, MLI, MLP, RRTS, UDR, USNA, VSH Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

Centene and Laboratory Corp. of America were among the healthcare stocks in the green on Tuesday, Feb. 6, amid a volatile trading day in the stock market.

Gilead Sciences Announces 10 Percent Increase In First Quarter 2018 Dividend

Gilead Sciences Announces 10 Percent Increase In First Quarter 2018 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 10% in the company's quarterly cash dividend, beginning in the first quarter of 2018.

Gilead Sciences Announces Fourth Quarter And Full Year 2017 Financial Results

Gilead Sciences Announces Fourth Quarter And Full Year 2017 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2017.

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

Maybe inverse and/or leveraged positions are perverse in nature.

Jacqueline K. Barton, Ph.D., Joins Gilead Sciences' Board Of Directors

Jacqueline K. Barton, Ph.D., Joins Gilead Sciences' Board Of Directors

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Jacqueline K.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Cramer: Step Away and Get Your Clients Better Prices

Cramer: Step Away and Get Your Clients Better Prices

You mean to tell me if the buyers walked away for 10 minutes they couldn't get these stocks lower?

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

TheStreet Quant Rating: C (Hold)